Analysis of the Strong Performance of Sanbo Brain Hospital (301293)

Sanbo Brain Hospital (301293) entered the strong stock pool mainly due to the

. The tracks it is in, such as brain-computer interface (human brain engineering) and smart medical care, are current hotspots in A-shares [1]. After closing with a 20% limit-up on January 5, 2026, it further attracted market attention, forming a positive cycle of “hot concept + limit-up attraction + capital inflow”. Technical indicators show that the turnover on that day was 755 million yuan, a significant increase from the previous day, and the main net inflow was 247 million yuan (accounting for 24.58% of total turnover) [1], pushing the stock price to break through the previous level; the average transaction cost of chips was 57.52 yuan, and the current stock price (70.78 yuan) is approaching the resistance level [1].

1. Concept Association Driven
   : Although the company’s brain-computer interface technology is still in the experimental stage and far from mature application [1], the market still associates it with the hot brain-computer interface track, reflecting the current A-share market’s pursuit of medical technology concepts.
2. Resonance of Capital and Sentiment
   : After the limit-up, the company’s popularity ranking in A-shares on the Sina Finance client rose to the 50th place [1]. Institutional holdings and the background of the new shareholder, Hong Kong Securities Clearing Company Limited [1], further enhanced market confidence, forming a resonance effect between capital and sentiment.
3. Coexistence of Risks and Supports
   : The technical resistance level (70.78 yuan) and the chip support level (57.52 yuan) form a clear range. At the same time, attention should be paid to the performance pressure from the 20.01% year-on-year decline in net profit attributable to shareholders from January to September 2025 [1], and the lock-up share release risk of 45.0413 million shares (accounting for 21.87% of the total share capital) on May 6, 2026 [2].

• Risks
  : Pullback risk at the technical resistance level [1], fundamental pressure from declining performance [1], selling pressure risk from lock-up share release [2], and sustainability risk of concept hype [1].
• Opportunities
  : Long-term development potential of medical technology tracks such as brain-computer interface, and the company’s industry position as a neurological specialist medical service provider.

Sanbo Brain Hospital’s recent strong performance is mainly driven by hot concepts and capital. Technically, it is close to the resistance level, and attention should be paid to fundamental risks and lock-up share release risks.